Tia Health (Tia), the modern women's healthcare platform, and Molecular Testing Labs (MTL), a leader in high-throughput and high-complexity clinical laboratory diagnostics, have partnered to offer to Tia's patients virtually and in clinics around the country the first FDA-cleared home-collection kit* that simultaneously detects four common sexually transmitted infections (STIs).
Tia & MTL launch first FDA-cleared home-collected STI test for 4 infections-discreet, fast, stigma-free.
This test uses the Abbott simpli-COLLECTTMSTI Testso patients can collect specimens from the comfort of their own home, providing an opportunity to test privately, without fear of stigma, and receive results more quickly than traditional testing methods – all while having their Tia provider as a trusted resource to provide results and any treatments.
Abbott's simpli-COLLECT STI Test is the only FDA-cleared home-collected test that can detect up to four common STIs – Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG) – in a single collection, making it efficient, cost-effective, and comprehensive. Patients can access the test kit through an order from one of Tia's clinicians, either via telemedicine or in person. Once a sample is collected, the patient can ship back their sample to the laboratory for testing and receive their results from a Tia provider.
This milestone marks the beginning of Tia's home testing journey and a major step forward in expanding access to high-quality personalized diagnostics for women. Tia's hybrid care model comprehensively empowers women to take charge of their health. With the addition of home testing, Tia can further deliver on this vision – giving women control and autonomy around their health and wellbeing throughout their lives.
“There is such synergy between home testing and Tia's care model, which puts patient choice and shared decision-making front and center. I have been in the field of sexual health for many years and have seen the positive impacts of home testing,” said Emily Rymland, DNP, FNP, Los Angeles Market Medical Director at Tia Health. “Stigma is a huge barrier to testing, and home sample collection reduces this barrier. People can now test without the fear of judgment. I often see people testing for the first time in their lives with home-based options. It is a fantastic way for our patients to continue to engage in care on their terms.”
MTL, a longtime innovator in both clinically and home-collected diagnostic testing, provides advanced logistics, custom EMR integrations, and claims reimbursement processes to ensure a seamless experience for this and many other tests. This partnership highlights the power of telehealth and at-home collection to transform access to care.
James York, MTL's Chief Commercial Officer and Head of Government Affairs, adds, “MTL collaborates with organizations across multiple markets to increase access to diagnostic testing, and we're grateful to find that mission alignment with Tia as a launch partner. By combining the FDA-cleared simpli-COLLECT STI Test with Tia's innovative care model, we're making it easier for patients to get the answers they need – discreetly, quickly, and reliably. We're proud to support a future where telehealth and home sample collection are not just alternatives, but essential tools in everyday healthcare.”
Media Contacts:Tia: press@asktia.comMolecular Testing Labs: media@moleculartestinglabs.com
About Tia Health:Tia Health is the only whole-body health partner for women at all stages of life. Tia offers in-clinic and virtual healthcare spanning primary care, gynecology, skin care, mental health, fertility, menopause and perimenopause support, and longevity care, with added services like acupuncture, nutrition, and more.
Tia's model focuses on optimizing women's immediate and long-term health-treating all ages and stages of life by addressing root causes, current symptoms, and working with women to develop actionable care plans that help them reach their health goals. For more information, visit www.asktia.com.
About Molecular Testing Labs:CareNexa, LLC dba Molecular Testing Labs is a leading CAP-accredited and CLIA-certified health science and precision laboratory diagnostics company on a mission to democratize access to healthcare. By pioneering high-complexity and high-throughput diagnostic testing and decentralized lab solutions, MTL reduces barriers to care, whether it be geography, cost, stigma, and/or inconvenience. With a commitment to health equity, MTL empowers patients and providers through innovative research and development, advanced logistics, cutting-edge technology, and compassionate billing. MTL's differentiated model combines scientific rigor, operational excellence, and inclusive access to help drive better health outcomes. For more information and to make the simpli-COLLECTTM STI Test available at your practice, visit www.moleculartestinglabs.com/sti-at-home-collection.
*The simpli-COLLECT STI Test is the only FDA-cleared test system intended for in vitro detection of CT, NG, TV, and MG in home-collected specimens from symptomatic and asymptomatic individuals. The simpli-COLLECT STI Test contains all the necessary components for the self-collection and transport of urine from male and female patients or vaginal swabs from female patients in their home, or in similar environments. The simpli-COLLECT Collection Kits may also be used to self-collect specimens in a clinic. The specimens are shipped to the laboratory for testing using the Alinity m STI Assay.
Pregnant women should not use the simpli-COLLECT Swab Collection Kit without first discussing with their healthcare provider.
For in vitro diagnostic use. Rx only.
https://edge.prnewswire.com/c/img/favicon.png?sn=SF82978&sd=2025-09-25
View original content:https://www.prnewswire.com/news-releases/tia-health-and-molecular-testing-labs-partner-to-launch-the-first-ever-fda-cleared-home-collected-4-plex-sti-test-302566626.html
SOURCE Molecular Testing Labs
https://rt.newswire.ca/rt.gif?NewsItemId=SF82978&Transmission_Id=202509251000PR_NEWS_USPR_____SF82978&DateId=20250925